C4 therapeutics receives study may proceed letter from u.s. fda to initiate phase 1/2 clinical trial of cft1946, an orally bioavailable bidac™ degrader, in braf-v600 mutant solid cancers

Phase 1/2 clinical trial will study cft1946 in braf-v600 mutant solid cancers including lung, colorectal and melanoma; trial initiation expected by year end 2022 phase 1/2 clinical trial will study cft1946 in braf-v600 mutant solid cancers including lung, colorectal and melanoma; trial initiation expected by year end 2022
CCCC Ratings Summary
CCCC Quant Ranking